A Cancer-Killing Virus Cut Bladder Cancer Recurrence by 68% in a Phase 3 Trial
On November 16, 2026, CG Oncology reported that cretostimogene grenadenorepvec, a virus-based therapy for bladder cancer, cut the risk of cancer coming back by 68% in PIVOT-006, a Phase 3 trial in people with intermediate-risk non-muscle invasive bladder cancer (NMIBC). No patients had serious (Grade 3 or higher) treatment-related side effects.
The company plans to submit a second Biologics License Application (BLA) for this group of patients in the second quarter of 2027. The full data will be presented at the Society of Urologic Oncology meeting on December 2, 2026.

The patients this is for
NMIBC is bladder cancer that has not grown into the bladder's muscle wall. Doctors remove the tumors through a scope in a procedure called TURBT. In intermediate-risk disease, the cancer is less aggressive, but it comes back often, which means repeated scopes and surgeries over many years.
After surgery, many of these patients are simply watched, because there is no approved therapy designed to prevent their cancer from returning. CG Oncology estimates about 50,000 patients in the US fall into this group each year.
How cretostimogene works
Cretostimogene is an oncolytic adenovirus, a virus engineered to multiply inside cancer cells and burst them while largely sparing healthy cells. It also carries the gene for GM-CSF, an immune-signaling protein that calls immune cells into the tumor. It is given directly into the bladder through a catheter.
The PIVOT-006 results
PIVOT-006 enrolled 367 patients at about 90 sites. After TURBT, patients were randomly assigned to receive cretostimogene or to be watched with surveillance alone. The median follow-up was 17 months as of October 26, 2026.
Cretostimogene reduced the risk of the cancer coming back by 68% compared with surveillance (hazard ratio 0.32, p<0.0001).
There were no Grade 3 or higher treatment-related side effects.
No patients stopped treatment because of side effects.
More than 700 patients have now been treated across the cretostimogene program.

What to watch
CG Oncology's first BLA covers a different group: high-risk NMIBC that no longer responds to BCG, the standard immunotherapy. That application, now broadened to include patients with papillary-only tumors, is expected to be complete by the end of March 2027. The second BLA, for intermediate-risk disease, is planned for the second quarter of 2027.
If approved, cretostimogene would be one of the first therapies to offer intermediate-risk patients more than watchful waiting. Key questions include how long the benefit lasts with more follow-up, and how the full results presented in December compare with other bladder-sparing options. Read our story on enGene's non-viral gene therapy for bladder cancer, another therapy given directly into the bladder.
The bottom line
In a randomized Phase 3 trial, a cancer-killing virus given into the bladder cut the risk of intermediate-risk bladder cancer coming back by 68% compared with surveillance, without serious treatment-related side effects. CG Oncology plans to seek FDA approval for this group in 2027.
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Learn it properly: Gene Therapy 101 walks you from DNA to approved therapies in 8 animated modules with quizzes.
Watch: 30-second gene therapy Shorts and in-depth lessons on Gene Tech Times Academy.
Read: The Life-Changing Power of Gene Therapy, real stories from the families behind the science.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
— T.N., Gene Tech Times




Comments